In a 60-year-old man with hypertension and hyperlipidemia who is taking losartan 100 mg daily and hydrochlorothiazide 50 mg daily, with a normal estimated glomerular filtration rate but a systolic blood pressure in the high 140 mm Hg range, what is the next step in management?

Add a Calcium Channel Blocker to Your Current Regimen

The next step is to add a long-acting dihydropyridine calcium channel blocker (such as amlodipine) to the existing losartan and hydrochlorothiazide regimen. 1

Rationale for This Recommendation

Your patient is on losartan 100 mg (maximum dose) and HCTZ 50 mg daily but remains uncontrolled with systolic BP in the high 140s. This represents Step 3 treatment failure according to current guidelines. 1

Current Medication Assessment

• Losartan 100 mg is at maximum recommended dose 2
• HCTZ 50 mg exceeds the recommended maximum of 25 mg for combination therapy 3, 1—this is a critical issue because doses above 25 mg provide minimal additional BP reduction but increase metabolic side effects 1

The Optimal Next Steps

Step 1: Add a dihydropyridine calcium channel blocker (CCB) while maintaining the ARB 1

• Start amlodipine 5 mg daily, which can be titrated to 10 mg if needed 1
• This creates the preferred three-drug combination: ARB + CCB + thiazide diuretic 1

Step 2: Consider switching HCTZ to a thiazide-like diuretic at appropriate dosing 1

• Replace HCTZ 50 mg with chlorthalidone 12.5-25 mg or indapamide 1.5 mg 1, 4
• Thiazide-like diuretics (chlorthalidone, indapamide) are superior to HCTZ for BP control and cardiovascular outcomes 1, 4
• A recent 2025 study demonstrated that losartan/chlorthalidone achieved better diastolic BP control and higher rates of target BP achievement compared to losartan/hydrochlorothiazide 4

Why This Approach Works

The combination of an ARB, CCB, and thiazide/thiazide-like diuretic represents the evidence-based standard for three-drug therapy 1. This combination:

• Targets multiple pathophysiologic mechanisms of hypertension 1
• Has demonstrated superior cardiovascular event reduction 1
• Is well-tolerated with complementary side effect profiles 1

Blood Pressure Targets

Your target should be systolic BP <130 mmHg 1

• The 2022 WHO guidelines recommend <130 mmHg systolic for patients with high cardiovascular risk 1
• The 2024 ESC guidelines recommend targeting 120-129 mmHg systolic if well tolerated 1
• Given this patient's age (60 years) and comorbidities (hyperlipidemia), he qualifies as higher cardiovascular risk 1

Practical Implementation

Preferred regimen modification:

1. Immediate change: Add amlodipine 5 mg daily to current regimen 1
2. Concurrent optimization: Switch from HCTZ 50 mg to chlorthalidone 12.5-25 mg daily 1, 4
3. Continue: Losartan 100 mg daily 2
4. Consider single-pill combinations to improve adherence 1

Expected Outcomes

Based on clinical trial data, adding a CCB to ARB/diuretic therapy typically reduces BP by an additional 10-15/5-10 mmHg 5, 6. The switch from HCTZ to chlorthalidone may provide an additional 2-3 mmHg systolic reduction 4.

Monitoring Plan

• Reassess BP in 1 month after medication changes 1
• Check serum potassium and creatinine within 2-4 weeks when changing diuretic therapy 1
• Achieve target BP within 3 months of initiating changes 1

If BP Remains Uncontrolled

Should BP remain >140/90 mmHg on the three-drug combination at optimal doses, Step 4 therapy involves adding spironolactone 25 mg daily (if serum potassium <4.6 mmol/L and eGFR adequate) 1. Alternative fourth-line agents include amiloride, doxazosin, or a beta-blocker 1.

Critical Pitfall to Avoid

Do not simply increase HCTZ beyond 25 mg 1, 3—the current dose of 50 mg is excessive and provides minimal additional benefit while increasing risks of hypokalemia, hyperglycemia, and hyperuricemia 1. The FDA-approved maximum for HCTZ in combination therapy is 25 mg 3.